Last reviewed · How we verify

Prophylaxis of repetitive paroxysmal supraventricular tachycardia — Treatment Landscape & Competitive Intelligence

Prophylaxis of repetitive paroxysmal supraventricular tachycardia (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prophylaxis of repetitive paroxysmal supraventricular tachycardia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Verapamil Hydrochloride Verapamil Hydrochloride Pfizer Inc. Calcium channel blocker L-type calcium channels (slow channels)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Prophylaxis of repetitive paroxysmal supraventricular tachycardia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prophylaxis of repetitive paroxysmal supraventricular tachycardia:

Cite this brief

Drug Landscape (2026). Prophylaxis of repetitive paroxysmal supraventricular tachycardia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prophylaxis-of-repetitive-paroxysmal-supraventricular-tachycardia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing